跳至主要内容
临床试验/ISRCTN24346473
ISRCTN24346473已完成未知

Primary care use of a C-Reactive Protein (CRP) Point of Care Test (POCT) to help target antibiotic prescribing to patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) who are most likely to benefit: a two-arm individually randomised controlled trial

Cardiff University (UK)0 个研究点目标入组 653 人开始时间: 2014年8月20日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
653

研究概览

简要总结

2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/28969667 2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31291514 (added 26/07/2019) 2020 results in https://pubmed.ncbi.nlm.nih.gov/32202490/ (added 24/03/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 21/02/2017:
  • 1. Has a current acute exacerbation [presenting with at least one of the following: Increased dyspnoea, increased sputum volume, increased sputum purulence] that has lasted for at least 24 hours and no longer than 21 days
  • 2. Diagnosis of COPD in clinical record/on COPD Practice register
  • 3. Age 40 years or more
  • 4. Able to provide informed consent
  • 5. Patient should be able to provide the primary outcome data at 2 and 4 weeks within the expected windows
  • Previous inclusion criteria:
  • 1. Adults aged 40
  • 2. Spirometry confirmed (at any time point prior to admission) COPD (post bronchodilator FEV1/FVC < 0.7)
  • 3. Patients with mild, moderate and severe disease: that is FEV1 of more than 30% of the predicted value as indicated by the age and the height of the person (GOLD stage 1-3)
  • 4. Have a current AECOPD, defined as, ?an event in the natural course of the disease characterized by a change in the patient's baseline dyspnoea, cough and/or sputum that is beyond normal day-to-day variations, is acute in onset and may warrant a change in regular medication?
  • 5. The exacerbation has lasted for at least 24 hours but equal to or less than 21 days
  • 6. Are able to attend the GP surgery
  • 7. Are able to provide informed consent and complete study procedures.

排除标准

  • Current exclusion criteria as of 21/02/2017:
  • 1. The responsible GP feels urgent referral to hospital is necessary
  • 2. Severe illness (e.g. suspected pneumonia, tachypnoea >30 breaths per minute, respiratory failure)
  • 3. Concurrent infection at another site (e.g. UTI, Cellulitis) that is likely to produce a systemic response
  • 4. Past history of respiratory failure or mechanical ventilation
  • 5. Currently on antibiotics or has had antibiotics for this acute exacerbation of COPD
  • 6. Active inflammatory condition (e.g. Flare up of rheumatoid arthritis, gout or polymyalgia rheumatica)
  • 7. Has cystic fibrosis, a current tracheostomy or bronchiectasis
  • 8. Immunocompromised (e.g. AIDS, taking systemic immunosuppressive therapy or receiving anti-cancer radiotherapy or chemotherapy)
  • 9. Currently pregnant
  • 10. Previously been recruited into the PACE study
  • Previous exclusion criteria:
  • 1. Very severe COPD (GOLD stage 4; FEV1 < 30% predicted)
  • 2. Coexisting infection (i.e. urinary tract infection, cellulitis)
  • 3. Suspected pneumonia or requiring immediate hospital admission
  • 4. History of requiring mechanical ventilation for an AECOPD
  • 5. Active chronic inflammatory condition (i.e. rheumatoid arthritis)
  • 6. Currently already taking high dose oral steroids (equivalent to 60mg per day or more of prednisolone)
  • 7. Has taken oral antibiotics in previous four weeks
  • 8. Life limiting malignancy
  • 9. Cystic fibrosis
  • 10. Current tracheotomy
  • 11. Bronchiectasis of any aetiology other than COPD
  • 12. Previously been recruited into the PACE study

研究者

发起方
Cardiff University (UK)

相似试验